Brief: Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak
28/05/2026 21:03
BRIEF-Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak May 28 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON’S EBOLA ANTIBODY RECOMMENDED BY WORLD HEALTH ORGANIZATION FOR INVESTIGATIONAL USE IN RESPONSE TO CURRENT BUNDIBUGYO EBOLAVIRUS OUTBREAK
REGENERON PHARMACEUTICALS INC: MAFTIVIMAB HAS BEEN RECOMMENDED TO BE STUDIED AS A MONOTHERAPY IN CURRENT OUTBREAK
REGENERON PHARMACEUTICALS - PREPARING MAFTIVIMAB SUPPLY FOR CLINICAL TRIALS; INMAZEB AVAILABLE IN DRC
REGENERON PHARMACEUTICALS INC: MAFTIVIMAB SHOWN BROAD ACTIVITY IN VITRO AGAINST MULTIPLE EBOLA SPECIES, INCLUDING BUNDIBUGYO
REGENERON PHARMACEUTICALS INC - SUPPLY OF INMAZEB IS ALREADY ON GROUND IN DRC
Source text: ID:nGNX463hDw
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement